Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitavastatin + Chemotherapy in Refractory NSCLC
NCT07351565Phase 1Not yet recruiting
- Sponsor
- Changchen Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of pitavastatin in non-small cell lung cancer (NSCLC), sponsored by Changchen Pharmaceutical. Primary endpoint: Objective Response Rate at 6 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
pitavastatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07351565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07351565.